Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Mouth and oropharyngeal Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


13 drugs have received FDA approval for Mouth and oropharyngeal Cancer . Amifostine, Docetaxel, Hydroxyurea, Ipilimumab, Leucovorin Calcium, Melphalan Hydrochloride, Nivolumab, Palifermin, Panitumumab, Pembrolizumab, Ramucirumab, Trastuzumab and Trifluridine
194 drugs have a clinical trial registered for Mouth and oropharyngeal Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 1284 clinical trials for Mouth and oropharyngeal Cancer,
670 of which have one or more drug interventions,
614 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 127 Cell Line Models for Mouth and oropharyngeal Cancer.

Source: COSMIC
(see details)

Chemistry


There are 20025 Compounds which have been tested in Mouth and oropharyngeal Cancer , 15078 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Mouth and oropharyngeal Cancer:
Esophageal Neoplasms
Esophageal Squamous Cell Carcinoma
Hypopharyngeal Neoplasms
Lip Neoplasms
Mouth Neoplasms
Oropharyngeal Neoplasms
Pharyngeal Neoplasms
Tongue Neoplasms

The following terms have been mapped from cancer.gov to Mouth and oropharyngeal Cancer:
Alone in patients whose disease got worse after treatment with chemotherapy that contained oxaliplatin, irinotecan hydrochloride, and a fluoropyrimidine
Anemia. It is used to treat megaloblastic anemia that occurs when the body does not get enough of a vitamin called folic acid. It is used by patients who cannot take the vitamin by mouth
Colorectal cancer in adults and children 12 years and older. It is used alone or with ipilimumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
Colorectal cancer in adults and children 12 years and older. It is used with nivolumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
Colorectal cancer that has gotten worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride.????
Colorectal cancer that has metastasized (spread to other parts of the body). It is used in adults who have already been treated with a fluoropyrimidine, oxaliplatin, irinotecan hydrochloride, and an anti-VEGF biologic therapy. Patients whose cancer does not have a mutation in the RAS gene should have also received an anti-EGFR therapy
Colorectal cancer that has metastasized. It is used with FOLFIRI in patients whose disease has gotten worse during or after treatment with bevacizumab, oxaliplatin, and a fluoropyrimidine
Multiple myeloma.It is used for palliative treatment in patients who cannot take melphalan by mouth. This use is approved for the Alkeran and Evomela brands
Oral mucositis that is severe. It is used in patients with leukemia or lymphoma who are being treated with high-dose chemotherapy and radiation therapy, followed by stem cell rescue
Squamous cell carcinoma of the head and neck (excluding the lip) that is locally advanced. It is used with chemoradiation
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in adults who have already received at least two treatments with a fluoropyrimidine and platinum chemotherapy and either a taxane or irinotecan and, in some cases, HER2/neu-targeted therapy
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in patients whose disease is HER2+. This use is approved for the Herceptin and Ogivri brands of trastuzumab
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced. It is used in patients whose disease has not been treated with chemotherapy
Xerostomia (dry mouth). It is used to decrease dryness in the mouth caused by radiation therapy after surgery in some patients with head and neck cancer